MA55069A - Nouvelles protéines de fusion spécifique à cd137 et gpc3 - Google Patents

Nouvelles protéines de fusion spécifique à cd137 et gpc3

Info

Publication number
MA55069A
MA55069A MA055069A MA55069A MA55069A MA 55069 A MA55069 A MA 55069A MA 055069 A MA055069 A MA 055069A MA 55069 A MA55069 A MA 55069A MA 55069 A MA55069 A MA 55069A
Authority
MA
Morocco
Prior art keywords
gpc3
fusion proteins
proteins specific
new fusion
new
Prior art date
Application number
MA055069A
Other languages
English (en)
Inventor
Aiba Rachida Siham Bel
Birgit Bossenmaier
Eva-Maria Hansbauer
Thomas Jaquin
Shane Olwill
Janet Peper-Gabriel
Corinna Schlosser
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of MA55069A publication Critical patent/MA55069A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055069A 2019-02-26 2020-02-25 Nouvelles protéines de fusion spécifique à cd137 et gpc3 MA55069A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19000100 2019-02-26

Publications (1)

Publication Number Publication Date
MA55069A true MA55069A (fr) 2022-01-05

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055069A MA55069A (fr) 2019-02-26 2020-02-25 Nouvelles protéines de fusion spécifique à cd137 et gpc3

Country Status (13)

Country Link
US (1) US20220153864A1 (fr)
EP (1) EP3931209A1 (fr)
JP (1) JP7476219B2 (fr)
KR (1) KR20210133254A (fr)
CN (1) CN113474359A (fr)
AU (1) AU2020229436A1 (fr)
BR (1) BR112021016829A2 (fr)
CA (1) CA3124441A1 (fr)
IL (1) IL284687A (fr)
MA (1) MA55069A (fr)
MX (1) MX2021010039A (fr)
SG (1) SG11202106353VA (fr)
WO (1) WO2020173897A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019073A (ko) * 2021-04-05 2024-02-14 사이토비아 테라퓨틱스, 엘엘씨. Nkp46 및 gpc3를 표적으로 하는 이중 특이적 항체 및 이의 사용 방법
CA3216342A1 (fr) * 2021-04-23 2022-10-27 Hassan ISSAFRAS Anticorps anti-gpc3, anticorps multispecifiques et methodes d'utilisation
CN117460745A (zh) * 2021-05-21 2024-01-26 百济神州有限公司 抗gpc3和抗cd137多特异性抗体及使用方法
WO2023036043A1 (fr) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 Molécule de liaison anti-cancéreuse et son utilisation
CN113912699A (zh) * 2021-10-14 2022-01-11 江南大学 一种新型治疗乳腺癌的fgf类似物及其应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
WO2023180523A1 (fr) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Procédé de purification de protéines de fusion

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
ATE307597T1 (de) 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1814988A2 (fr) 2004-11-26 2007-08-08 Pieris AG Compose a affinite pour l'antigene associe au lymphocyte t cytotoxique (ctla-4)
WO2007038619A2 (fr) 2005-09-27 2007-04-05 Amunix, Inc. Produits pharmaceutiques proteiques et utilisations de ceux-ci
EP2046820B1 (fr) 2006-08-01 2010-10-20 Pieris AG Mutéines de lipocaline lacrymale et procédés permettant d'obtenir lesdites mutéines
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107820500B (zh) 2015-05-04 2022-03-01 皮里斯制药有限公司 Cd137特异性的蛋白
EP3292148B1 (fr) * 2015-05-04 2024-01-24 Pieris Pharmaceuticals GmbH Polypeptide de fusion anti-cancéreux
RU2756318C2 (ru) 2015-05-18 2021-09-29 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)
ES2938525T3 (es) * 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
WO2018087108A1 (fr) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Protéines spécifiques de cd137
EP3565595A4 (fr) * 2017-01-06 2021-03-17 Momenta Pharmaceuticals, Inc. Compositions et procédés associés à des constructions de domaine de liaison à un antigène fc manipulé
EP3638700A4 (fr) 2017-06-14 2021-04-21 Dingfu Biotarget Co., Ltd Hétérodimère protéique et utilisation de celui-ci

Also Published As

Publication number Publication date
BR112021016829A2 (pt) 2021-10-19
IL284687A (en) 2021-08-31
SG11202106353VA (en) 2021-07-29
MX2021010039A (es) 2021-09-21
US20220153864A1 (en) 2022-05-19
EP3931209A1 (fr) 2022-01-05
KR20210133254A (ko) 2021-11-05
JP7476219B2 (ja) 2024-04-30
CN113474359A (zh) 2021-10-01
WO2020173897A1 (fr) 2020-09-03
JP2022523524A (ja) 2022-04-25
CA3124441A1 (fr) 2020-09-03
AU2020229436A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MA55069A (fr) Nouvelles protéines de fusion spécifique à cd137 et gpc3
MA51291A (fr) Protéines de fusion il-2 fc modifiées
MA53982A (fr) Protéines hétérodimères fusionnées à un fragment fc
DK3830120T3 (da) Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1
DK4011908T3 (da) Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
MA50942A (fr) Protéines de liaison à l'adn modifiées
DK3265478T3 (da) Fusionsproteiner, der omfatter et bindingsprotein og et interleukin-15-polypeptid med reduceret affinitet til il15ra, og terapeutiske anvendelser deraf
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MA53616A (fr) Protéines bispécifiques modifiées
DK3280432T3 (da) Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
IL275248A (en) Fusion protein of a therapeutic enzyme with a new structure and its use
DK3137595T3 (da) Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse
MA52994A (fr) Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
DK3380119T3 (da) Fmdv- og e2-fusionsproteiner og anvendelser deraf
DK3728288T3 (da) Fremgangsmåder til forbedret fjernelse af urenheder under protein a-kromatografi